Tscan Therapeutics Inc (TCRX)
1.3400 -0.0400 (-2.90%) 12:27 ET [NASDAQ]
1.3200 x 100 1.3400 x 300
Realtime by (Cboe BZX)
1.3200 x 100 1.3400 x 300
Realtime 1.3800 unch (unch) 08:00 ET
for Tue, Apr 1st, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 178,689 | 133,118 | 242,159 | 140,513 | 133,359 |
Marketable Securities | 111,421 | 138,002 | 55,517 | 22,270 | 58,685 |
TOTAL | $292,722 | $274,085 | $299,530 | $164,721 | $194,237 |
Non-Current Assets | |||||
PPE Net | 7,242 | 7,461 | 7,615 | 7,201 | 7,742 |
Investments And Advances | 1,766 | 1,807 | 1,746 | 1,647 | 1,647 |
Other Non-Current Assets | 69,388 | 64,674 | 65,980 | 67,263 | 68,523 |
TOTAL | $78,396 | $73,942 | $75,341 | $76,111 | $77,912 |
Total Assets | $371,118 | $348,027 | $374,871 | $240,832 | $272,149 |
Liabilities | |||||
Current Liabilities | |||||
Short Term Debt | N/A | N/A | 10,336 | 6,797 | 3,347 |
Accounts payable and accrued liabilities | 4,278 | 3,647 | 3,110 | 2,123 | 2,374 |
Accrued Expenses | 15,410 | 11,181 | 10,808 | 8,786 | 10,716 |
TOTAL | $35,956 | $28,660 | $38,572 | $31,479 | $29,820 |
Non-Current Liabilities | |||||
Long Term Debt | 32,072 | 30,647 | 20,112 | 23,449 | 26,700 |
Deferred Revenues | 11,698 | 9,934 | 10,704 | 10,435 | 10,137 |
aiOther Non-Current Liabilities | 60,874 | 55,957 | 57,011 | 58,179 | 59,140 |
TOTAL | $94,192 | $90,280 | $81,078 | $86,386 | $91,462 |
Total Liabilities | $130,148 | $118,940 | $119,650 | $117,865 | $121,282 |
Shareholders' Equity | |||||
Shares Outstanding, K | 56,591 | 53,371 | 52,974 | 52,863 | 47,882 |
Common Shares | 6 | 6 | 6 | 5 | 5 |
Retained earnings | -375,096 | -339,287 | -309,400 | -277,739 | -247,597 |
Other shareholders' equity | 51 | 0 | 0 | 0 | 0 |
TOTAL | $240,970 | $229,087 | $255,221 | $122,967 | $150,867 |
Total Liabilities And Equity | $371,118 | $348,027 | $374,871 | $240,832 | $272,149 |